Recent Research Progress of Extramedullary Plasmacytoma --Review.
10.19746/j.cnki.issn.1009-2137.2023.02.045
- Author:
Ning LIU
1
,
2
;
Juan ZHAO
1
,
2
;
X I YUAN
1
,
2
;
Ya-Ming XI
3
Author Information
1. The First Clinical Medical College of Lanzhou University
2. Lanzhou 730000, Gansu Province, China.
3. Department of Hematology, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China. E-mail：xiyaming02@163.com.
- Publication Type:Journal Article
- Keywords:
extramedullary plasmacytoma;
extramedullary lesions;
multiple myeloma
- MeSH:
Humans;
Plasmacytoma/surgery*;
Prognosis;
Multiple Myeloma/genetics*;
Hematopoietic Stem Cell Transplantation
- From:
Journal of Experimental Hematology
2023;31(2):607-611
- CountryChina
- Language:Chinese
-
Abstract:
Extramedullary plasma cell tumor (EMP) is a kind of plasma cell tumor, and its pathogenesis is not completely clear. According to whether it is independent of myeloma disease, it can be divided into primary and secondary EMP, which have different biological and clinical characteristics. Primary EMP has low invasion, fewer cytogenetic and molecular genetic abnormalities and good prognosis, and surgery and / or radiotherapy are the mainly treatments. Secondary EMP, as the extramedullary invasive progression of multiple myeloma (MM), is often accompanied by high-risk cellular and molecular genetic abnormalities and poor prognosis, chemotherapy, immunotherapy and hematopoietic stem cell transplantation are the mainly treatment. This paper reviews the latest research progress of EMP in the pathogenesis, cytogenetics molecular genetics and treatment, so as to provide reference for clinical work.
